Cyfuse Biomedical KK

Cyfuse Biomedical KK Interest Coverage

The Interest Coverage Ratio of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is -98.18. In the previous year, Interest Coverage Ratio was -71.55 — a change of 37.23% (lower).

Interest Coverage

-98.18

YoY

37.23%

Last updated:

Interest Coverage Ratio of Cyfuse Biomedical KK is 2024 -98.18 . Interest Coverage Ratio of Cyfuse Biomedical KK was 2023 -71.55 . It decreases by 37.23% lower compared to the previous year.

The Cyfuse Biomedical KK Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2020
-64.32 JPY
Jan 1, 2021
13.95 JPY
Jan 1, 2022
-49.25 JPY
Jan 1, 2023
-71.55 JPY
Jan 1, 2024
-98.18 JPY
The Cyfuse Biomedical KK Interest Coverage history
YEARInterest CoverageYoY
-98.18+37.23%
-71.55+45.27%
-49.25-453.14%
13.95-121.68%
-64.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

Interest Coverage Ratio of Cyfuse Biomedical KK is -98.18 in 2024.

Interest Coverage Ratio of Cyfuse Biomedical KK changed from -71.55 to -98.18, representing a 37.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Cyfuse Biomedical KK with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK